These results demonstrate that therapeutic treatment with ActRIIA-Fc—unlike standard PAH therapy with sildenafil—robustly inhibits inflammation and perivascular monocytic infiltration as important components of its tissue-level anti-remodeling activity in PH models. Here, ACVR2A is linked to pulmonary arterial hypertension.